Zobrazeno 1 - 10
of 394
pro vyhledávání: '"Robert J. Glynn"'
Autor:
Rishi J. Desai, Seoyoung C. Kim, Daniel H. Solomon, Hemin Lee, Michael E. Weinblatt, Mengdong He, Robert J. Glynn, Ajinkya Pawar
Publikováno v:
Seminars in Arthritis and Rheumatism. 51:1242-1250
Aims : Patients with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE), likely related to underlying inflammation. We examined VTE risk associated with two commonly used immunomodulators in RA patients, methotrexate and
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:1011-1017
Polypharmacy is common among patients taking prescription opioids long-term, and the codispensing of interacting medications may further increase opioid overdose risk. To identify nonopioid medications that may increase opioid overdose risk in this p
Publikováno v:
Diabetes Care
OBJECTIVE We evaluated recent use trends and predictors of first-line antidiabetes treatment in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Using two large U.S. health insurance databases (Clinformatics and Medicare), we identified adu
Autor:
Katherine P. Liao, Venkatesh Mani, Pamela M. Rist, Paul M. Ridker, Zahi A. Fayad, Fengxin Lu, Joan M. Bathon, Rachel Broderick, Robert J. Glynn, Nina P. Paynter, Ahmed Tawakol, Jon T. Giles, Kathleen M M Vanni, Meredith Murray, Daniel H. Solomon
Publikováno v:
ACR Open Rheumatology, Vol 3, Iss 6, Pp 371-380 (2021)
ACR Open Rheumatology
ACR Open Rheumatology
Individuals with rheumatoid arthritis (RA) are at increased risk for atherosclerotic cardiovascular disease (ASCVD) events relative to the general population, potentially mediated by atherosclerotic plaques that are more inflamed and rupture prone. W
Publikováno v:
Pediatric Infectious Disease Journal. 40:681-687
Background In the United States, pertussis circulation persists and primarily infects infants and children, despite routine vaccinations. To minimize infant morbidity and mortality from the disease before the first DTaP dose, the Advisory Committee o
Autor:
Daniel H. Solomon, Robert J. Glynn, Paul F. Dellaripa, Paul M. Ridker, Nina P. Paynter, Jeffrey A. Sparks, Chang Xu
Publikováno v:
Arthritis & Rheumatology. 72:2065-2071
OBJECTIVE We previously reported that low-dose methotrexate (MTX) was associated with an increased risk of pulmonary adverse events (AEs) in a large randomized, placebo-controlled trial. Herein, we report details on the predictors and severity of pul
Publikováno v:
Canadian Journal of Diabetes. 44:628-635
Objectives Both type 2 diabetes (T2DM) and dementia have multifactorial etiologies. Both are associated with aging and have well-recognized lifestyle, cardiovascular and psychosocial risk factors. However, uncertainty exists in the literature with re
Autor:
H. Diana Rosas, Dennis J. Selkoe, Robert J. Glynn, Vasiliki Patsiogiannis, Dominic M. Walsh, David Mengel, Andre Strydom, Amy Torres, Brian G. Skotko, Wen Liu, Florence Lai
Publikováno v:
Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-11 (2020)
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy
Background Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD), but diagnosis of AD in DS is challenging due to the intellectual disability which accompanies DS. When disease-modifying agents for AD are approved, reliabl
Autor:
Yinzhu Jin, Sebastian Schneeweiss, Robert J. Glynn, Kenneth D. Mandl, Kueiyu Joshua Lin, Shawn N. Murphy, Gary E. Rosenthal
Publikováno v:
Clinical Epidemiology
Kueiyu Joshua Lin,1,2 Gary E Rosenthal,3 Shawn N Murphy,4,5 Kenneth D Mandl,6 Yinzhu Jin,1 Robert J Glynn,1 Sebastian Schneeweiss1 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvar
Autor:
Deborah J. Wexler, Mehdi Najafzadeh, Ajinkya Pawar, Lily G. Bessette, Anouk Deruaz-Luyet, Patorno E Elisabetta, Sebastian Schneeweiss, Julie M. Paik, Robert J. Glynn, Kimberly G. Brodovicz
Publikováno v:
Diabetes Obes Metab
Objective Over 99% of the EMPA-REG OUTCOME trial participants had established cardiovascular disease (CVD). We aimed to investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating empagliflozin vs dipeptidyl pep